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the CC BY-NC-ND license (http://creaAbstract Objective: Although the utility of immunohistochemistry (IHC) for assessing
mismatch repair (MMR) protein expression has been demonstrated in solid tumors including pri-
mary prostate cancer (PCa), its utility has not been assessed in castration-resistant PCa
(CRPC).
Methods: Tissue microarrays were constructed from 127 radical prostatectomies and 155 CRPC
metastases from 50 patients. MMR (MLH1, MSH2, MSH6, and PMS2) expression was assessed by
IHC and gene expression arrays. Associations between MMR protein expression in PCa and CRPC
andbiochemical recurrence (BCR) or time fromdiagnosis to death respectivelyweredetermined.
Results: There was no correlation between levels of MMR protein and BCR. Absence of MSH2 and
MSH6was themost pronounced at 15% and 22% in PCa and 17.8% and 16% inCRPCpatients, respec-
tively. MSH2 andMSH6 protein were absent in 9.4% and 8% of PCa and CRPC respectively. Absence
of individual MMR proteins did not correlate with BCR or time from diagnosis to death. However
absent MSH2/MSH6 in CRPCwas associatedwith shorter time to death (pZ 0.0006). Loss of MSH2
was verified at the gene expression level. This finding correlated with microsatellite instability
previously reported in this CRPC cohort.ary Cancer Research Laboratory, Department of Urology, Box 356510, University of Washington,
(C. Morrissey).
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224 B. Nghiem et al.Conclusion: The absence of MLH1, MSH2, MSH6, and PMS2 protein and combinations thereof
are frequent in PCa. Loss of MSH2/MSH6 protein may predict poor outcome in patients with
CRPC.
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MLH1, MSH2, MSH6, and PMS2 are all mismatch repair (MMR)
enzymes that are associated with microsatellite instability
in cancer [1]. Microsatellite instability has been observed in
prostate cancer (PCa) with Christians et al. [2] reporting
one of 30 patients displaying instability and Suzuki et al. [3]
reporting seven of 48 patients displaying stability, however,
these differences may reflect differences in the patient
populations studied. To repair mismatched nucleotides the
MLH1, MSH2, MSH6, and PMS2 MMR enzymes form a complex
through the initial heterodimerization of MSH2/MSH6 which
first identifies the mismatch and accommodates the MLH1/
PMS2 heterodimer to initiate repair of the mismatch defect
[4,5]. Our study focused on assessing the expression of
MLH1, MSH2, MSH6, and PMS2 in PCa by immunohisto-
chemistry (IHC).
Mismatch repair enzyme loss has previously been
assessed by IHC in PCa. In a study of 81 PCa’s on a tissue
microarray there was no complete loss of MLH1 protein [6].
Interestingly PMS2 expression has been shown to be
elevated in PCa [7] and has been described as a predictor
for biochemical recurrence after radical prostatectomy [8].
MSH2 IHC staining intensity has been shown to correlate
with Gleason score, overall and disease-free survival in PCa
[6,9,10]. Additional IHC studies have focused on patient
populations that are carriers for MMR enzyme deficiencies
considered to be more at risk for the development of PCa
[11e14]. Loss of MLH1, PMS2 and MSH2 proteins has also
been described in PCa cell lines (DU145, LNCaP, p69SV40T,
M2182, and M12) [15e17].
Fifteen percent of colorectal cancers have a hyper-
mutated phenotype and microsatellite instability [18]. The
hypermutated phenotype has also been described in PCa
[19]. Pritchard et al. [20] estimated that 12% of CRPCs are
hypermutated, and that all of the hypermutated cancers
had mismatch repair gene mutations and microsatellite
instability.
We analyzed a primary PCa cohort and further analyzed
the Pritchard cohort to further characterize MMR expres-
sion in CRPC by IHC. We observed that the absence of MSH2
and MSH6 expression by IHC are frequent events in both
primary PCa and CRPC. Furthermore, we found no sub-
stantial decrease in MMR protein levels by IHC in CRPC
versus primary PCa. Contrary to other IHC studies of MMR
protein expression we did not observe any association be-
tween MMR protein expression and time to biochemical
recurrence. However, in our cohort of CRPC patients the
absence of MSH2/MSH6 expression by IHC was associated
with rapid disease progression.2. Materials and methods
2.1. Tissue acquisition and microarray construction
Human PCa specimens were obtained as part of the Univer-
sity of Washington Medical Center Prostate Cancer Donor
Program, which is approved by the University of Washington
Institutional Review Board [21]. All specimens for IHC were
formalin fixed (and, for bone specimens, decalcified in for-
mic acid), paraffin embedded and examined histologically
for presence of non-necrotic tumor. Tissue microarrays
(TMA)were constructedwith 1mm-diameter duplicate cores
from primary PCa (consisting of 127 radical prostatectomy
specimens; clinical data are detailed in Supplemental
Table 1), and CRPC (consisting of 155 CRPC metastases
including 73 visceral metastases and 82 bone metastases
from 50 patients within 8 h of death, up to 4 sites per pa-
tient). The clinical data have been previously reported [22].
2.2. IHC
Five micron thick sections of formalin-fixed paraffin-
embedded tissue were deparaffinized. Antigen retrieval
was performed with heat-induced epitope retrieval.
Endogenous peroxidase and biotin were blocked and sec-
tions were then blocked with 5% normal goat-horse-chicken
serum, and incubated with the primary antibody. After
washing with PBS, slides were incubated with biotinylated
secondary antibody (Vector Laboratories Inc., Burlingame,
CA, USA), followed by ABC reagent (Vector Laboratories
Inc.) and stable diaminobenzidine (Invitrogen Corp., Wal-
tham, MA, USA). All sections were lightly counterstained
with hematoxylin and mounted with Cytoseal XYL (Richard
Allan Scientific). Mouse or rabbit immunoglobulin-G was
used at the same concentration as the primary antibody for
negative controls. Antibodies and dilutions used for IHC are
described in Supplemental Table 2.
2.3. IHC assessment
All assessments were performed on 1 mm-diameter cores
from primary PCa and CRPC.
2.3.1. MMR enzyme expression levels
Immunostaining of nuclei was assessed using a quasi-
continuous score system, created by multiplying each in-
tensity level (“0” for no brown color, “1” for faint and fine
brown chromogen deposition, and “2” for clear and coarse
granular chromogen clumps) with the percentage of cells
stained at each respective intensity. We then summed all
Figure 1 Nuclear mismatch repair protein expression in primary prostate cancer and castration-resistant prostate cancer me-
tastases. Immunohistochemistry analysis of MLH1, MSH2, MSH6, and PMS2 in primary PCa (A) and CRPC metastases (B). Median
nuclear staining was reduced in CRPC metastases when compared to primary PCa. Of note, median MSH6 staining was lower than
MLH1, MSH2, and PMS2.
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0 to 200) [23].
2.3.2. Presence or absence of MMR enzyme expression
MMR protein positive patients were defined as those pa-
tients where nuclei of any tumor cell within the patient
specimen stained positive. Negative patients were defined
as those patients where there was an absence of nuclear
staining in any tumor cell in the patient specimen. For
metastasis specimens where multiple metastases were
available for analysis from one patient all sites of metas-
tasis needed to be negative for the patient to be defined as
a negative patient. Samples with missing or damaged sec-
tions were excluded from analysis.
2.4. RNA isolation, amplification and microarray
hybridization
Gene expression data have been published [24] (GEO acces-
sion #GSE77930). Briefly, total RNA was isolated from laser
capture micro dissected frozen CRPC metastases, using the
Arcturus Pico Pure RNA Isolation Kit (Thermo Fisher, Wal-
tham, MA, USA) and DNAse treated using the Qiagen RNase-
Free DNase Set (Hildan, Germany). RNA was amplified for
two rounds using the Ambion Message Ampa RNA Kit (Wal-
tham, MA, USA). Agilent 44 K whole human genome expres-
sion oligonucleotidemicroarrays (Agilent Technologies, Inc.)
were used to profile the CRPC metastases.
2.5. Statistical analysis
Significance of differences for the transcript analyses was
calculated using a student’s t-test. P values  0.05 indi-
cated statistical significance. Biochemical recurrence and
survival proportions were compared by KaplaneMeier plot
with log-rank test using GraphPad Prism version 6.02
(La Jolla, CA, USA).
3. Results
3.1. Mismatch repair enzyme levels in primary PCa
Nuclear staining was verified by IHC for all four MMR pro-
teins (Supplemental Figs. 1e4). Nuclear scores ranged fromnegative (0) to completely positive (200). To determine if
the levels of MMR enzyme expression were associated with
biochemical recurrence we compared the outcomes of high
(100) vs. low (<100) expressing MLH1, MSH2, and PMS2
patients. Since the mean staining score of MSH6 was
20.3  29.5, we used a threshold value of high (50) vs. low
(<50) (Fig. 1A). There was no statistically significant asso-
ciation of protein expression level with biochemical recur-
rence for each of the MMR proteins (Supplemental Fig. 5).
3.2. Mismatch repair enzyme levels in CRPC
To determine if levels of MMR proteins are lower in patients
with advanced disease we compared the nuclear score in
CRPC relative to primary PCa. Mean expression levels
dropped from 80.1  29.4 to 59.2  37.3 for MLH1,
50.1  38.3 to 20.1  31.5 for MSH2, 20.3  29.5 to
15.2  23.8 for MSH6, and 68.1  33.5 to 44.7  40.6 for
PMS2 in primary PCa compared to CRPC (Fig. 1). Thus we
found moderate decreases in the expression of all of the
MMR enzymes in CRPC relative to primary PCa. In addition,
we found that different metastases within the same patient
expressed each protein at different levels, however, no
differences in MMR enzyme expression were observed be-
tween bone and visceral metastases.
3.3. Complete loss of mismatch repair enzyme
levels in primary PCa
Since the complete loss of protein expression by IHC has
been used to identify patients and specimens with MMR
deficiency and microsatellite instability, we switched our
focus to evaluating specimens with complete loss of MMR
expression in both primary PCa and CRPC. In primary PCa
we determined that 5.0%, 15.0%, 17.8%, and 11.2% of the
patients specimens did not stain for MLH1, MSH2, MSH6, and
PMS2, respectively (Table 1). Since MLH1 forms a functional
heterodimer with PMS2 and MSH6 forms a functional het-
erodimer with MSH2, we also determined the absence of
MLH1/PMS2 (2.6%) and MSH2/MSH6 (9.4%) in primary PCa.
We observed an absence of staining for all four MMR pro-
teins in 2.6% of the primary PCa specimens (Table 1;
Supplemental Table 3). Absent staining was not associated
with biochemical recurrence for any of the four MMR pro-
teins or MSH2/MSH6 in primary PCa (Supplemental Fig. 6).
Table 1 Absence of MMR protein expression by IHC in primary PCa and CRPC metastasis. The absence of MMR protein
expression in primary PCa and CRPC metastases expressed as a % of total patients/cohort. Absence of MSH2 and MSH6 expression
was pronounced in both primary PCa and CRPC patients.
MLH1 MSH2 MSH6 PMS2 MSH2/MSH6 MLH1/PMS2 MLH1/MSH2/MSH6/PSM2
Primary PCa
Total patient (n) 119 120 118 116 117 116 116
Negative patient (n) 6 18 21 13 11 3 3
Negative (%) 5.0 15.0 17.8 11.2 9.4 2.6 2.6
Metastatic CRPC
Total Patient (n) 50 50 50 50 50 50 50
Negative Patient (n) 3 11 8 5 4 3 1
Negative (%) 6.0 22.0 16.0 10.0 8.0 6.0 2.0
CRPC, castration-resistant prostate cancer; IHC, immunohistochemistry; MMR, mismatch repair; PCa, prostate cancer.
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levels in CRPC
In CRPC we determined that 6.0%, 22.0%, 16.0%, and 10.0%
of the patients specimens did not stain for MLH1, MSH2,
MSH6, and PMS2, respectively (Table 1). Six percent of the
CRPC patients had no observable MLH1 and PMS2 (MLH1/
PMS2) protein expression and 8% had no observable
expression of MSH2 and MSH6 (MSH2/MSH6). MMR protein
staining for all four MMR proteins was absent in 2.0% of the
CRPC patients (Table 1; Supplemental Table 4). We
determined from previously published data that all four
MSH2/MSH6-negative patients had microsatellite insta-
bility [20]. The absence of staining was not associated
with a shortened time from diagnosis to death for the fourFigure 2 Absence of MSH2/MSH6 in castration-resistant prostate
from diagnosis to death. KaplaneMeier analysis on the individual
staining was not associated with shortened time from diagnosis to de
MSH6, and D is PMS2.) in CRPC patients. (E) KaplaneMeier analysis o
MSH2/MSH6 revealed a significant trend towards a shortened surviindividual MMR proteins in CRPC patients (Fig. 2AeD).
However, the absence of MSH2/MSH6 protein expression
was associated with a shortened time from diagnosis to
death (p Z 0.0006) (Fig. 2E). Loss of MSH2 and MSH6
protein staining usually indicates a germline MSH2 muta-
tion [25] therefore we compared gene expression in CRPC
specimens to determine if the loss of MSH6 transcript was
associated with the loss of MSH2 transcript. The MSH2
transcript was significantly decreased in patients missing
MSH2/MSH6 protein relative to all other specimens in
the CRPC patients (p < 0.0001; Supplemental Fig. 7).
The MSH6 transcript was also significantly decreased in
patients missing MSH2/MSH6 protein relative to all
other specimens in the CRPC patients (p Z 0.0018;
Supplemental Fig. 7).cancer (CRPC) metastases is associated with shortened time
mismatch repair (MMR) enzymes determined the absence of
ath for each of the four MMR proteins (A is MLH1, B is MSH2, C is
f MSH2/MSH6 (nZ 4) vs. all other patients (nZ 46). Absence of
val time (p Z 0.0006).
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There is precedence for using TMAs to assess MMR protein
expression in cancer specimens. In a study of colon cancer
Hendricks et al. [26] compared whole slides to a TMA from a
cohort of 129 patients and assessed MLH1, MSH2, and MSH6
protein expression and MSI. The TMA, showed a concor-
dance of 85%, 95%, and 75% for MLH, MSH2, and MSH6,
respectively. TMAs have also been used to determine MMR
protein expression in ovarian cancer, endometrial cancer,
and PCa [10,27,28].
Differential expression of MMR enzymes has been asso-
ciated with disease recurrence in PCa. Velasco et al. [9]
observed that decreased MSH2 expression in PCa speci-
mens from 73 patients was associated with a decreased risk
for time to PSA recurrence after radical prostatectomy
(p Z 0.08). Prtilo et al.[10] in a cohort of 223 men also
demonstrated that patients with low MSH2 expressing tu-
mors had a significant survival advantage (p < 0.0004).
Additionally, in a cohort of 58 patients Burger et al.[6]
observed a significant association between moderate/
strong MSH2 and tumor recurrence (p Z 0.039). Further,
Norris et al.[8] in a cohort of 166 patients determined the
mean level of PMS2 protein was higher in tumors of patients
with high grade tumors who recurred, compared with non-
recurrent patients and that PMS2 was an independent
predictor of time-to-recurrence (P < 0.001). However, in
our cohort of 127 patients we observed no association of
MLH1, MSH2, MSH6, or PMS2 expression levels with recur-
rence. The discordance between our study and those of
others may be due to differences in patient numbers,
immunohistochemical methods, follow-up times or the co-
horts studied. For example, while approaching significance
Velasco et al. [9] did not observe a statistically significant
association of MSH2 with biochemical recurrence, Burger
et al. [6] examined the association of MSH2 with recurrence
over 3 years and Norris et al. [8] focused on patients with
aggressive disease. However, Prtilo et al. [10] assessed
MSH2 in considerably more patient specimens (n Z 243)
using similar methods and determined that MSH2 expression
correlated with biochemical disease-free survival
(P Z 0.018).
Our study focused more on the absence of staining
rather than changes in MMR protein expression levels. We
reasoned that since the loss of MMR function leads to MSI
only the complete loss of any MMR protein would lead to
genetic instability and a more aggressive tumor phenotype.
Nevertheless, we did not observe any significant decrease
in time to recurrence in patients where we observed an
absence of any of the four MMR proteins (MLH1, MSH2,
MSH6, or PMS2) or combinations thereof. When comparing
the absence of the four MMR proteins in primary vs.
castration resistant disease we determined there was little
to no difference in the incidence of MMR protein negativity
between the hormone naı¨ve and late stage CRPC disease.
This result suggests that the absence of MMR protein
expression does not necessarily lead to an increase in
disseminated disease in hormone naı¨ve tumors.
Pritchard et al. [20] have shown that complex structural
rearrangements in mismatch DNA repair genes MSH2 and
MSH6 are a major mechanism that result in MSI. Our datacomprise some of the individuals in the Pritchard data set.
We determined the four CRPC patients that were negative
for both MSH2 and MSH6 protein in CRPC patients from the
Pritchard dataset had MSI [20] and a shorter time from
diagnosis to death. Furthermore, we determined there was
a significant decrease in MSH2 and MSH6 at the transcript
level in the MSH2/MSH6 negative specimens (which was
more pronounced for MSH2).
The loss of MSH6 protein expression usually follows the
loss of MSH2 expression suggesting that the absence of both
proteins in a patient specimen may clearly define a group of
patients in PCa that have MSI. Whether MMR enzyme inac-
tivity and subsequently MSI in advanced CRPC provides the
tumor with more effective ways to evade androgen depri-
vation therapy and conventional treatment, remains to be
seen.
5. Conclusion
The absence of MLH1, MSH2, MSH6, and PMS2 protein and
combinations thereof are frequent in PCa. The number of
patients whose cancers did not express any MMR protein by
IHC was similar in primary PCa and CRPC. No significant
difference in biochemical recurrence was observed be-
tween patients with tumor tissues expressing MMR proteins
versus negative cancers. These data suggest that (i) the
frequency of MSH2-/MSH6- tumors are similar in primary
PCa and CRPC, and (ii) the absence of MSH2/MSH6 in me-
tastases may impact survival in patients with CRPC.
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